Skip to main content
×
Home
    • Aa
    • Aa
  • Access
  • Open access
  • Cited by 22
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Gulla, Christine Selbaek, Geir Flo, Elisabeth Kjome, Reidun Kirkevold, Øyvind and Husebo, Bettina S. 2016. Multi-psychotropic drug prescription and the association to neuropsychiatric symptoms in three Norwegian nursing home cohorts between 2004 and 2011. BMC Geriatrics, Vol. 16, Issue. 1,


    Karel, Michele J. Teri, Linda McConnell, Eleanor Visnic, Stephanie and Karlin, Bradley E. 2016. Effectiveness of Expanded Implementation of STAR-VA for Managing Dementia-Related Behaviors Among Veterans. The Gerontologist, Vol. 56, Issue. 1, p. 126.


    Lichtwarck, Bjørn Selbaek, Geir Kirkevold, Øyvind Rokstad, Anne Marie Mork Benth, Jūratė Šaltytė Myhre, Janne Nybakken, Solvor and Bergh, Sverre 2016. TIME – Targeted interdisciplinary model for evaluation and treatment of neuropsychiatric symptoms: protocol for an effectiveness-implementation cluster randomized hybrid trial. BMC Psychiatry, Vol. 16, Issue. 1,


    Mitchell, Janet I. Long, Janet C. Braithwaite, Jeffrey and Brodaty, Henry 2016. Social-Professional Networks in Long-Term Care Settings With People With Dementia: An Approach to Better Care? A Systematic Review. Journal of the American Medical Directors Association, Vol. 17, Issue. 2, p. 183.e17.


    Newell, Jeffery Yesavage, Jerome A. Taylor, Joy L. Kraemer, Helena C. Munro, Cynthia A. Friedman, Leah Rosenberg, Paul B. Madore, Michelle Chao, Steven Z. Devanand, D.P. Drye, Lea T. Mintzer, Jacobo E. Pollock, Bruce G. Porsteinsson, Anton P. Schneider, Lon S. Shade, David M. Weintraub, Daniel Lyketsos, Constantine G. and Noda, Art 2016. Sedation mediates part of Citalopram's effect on agitation in Alzheimer's disease. Journal of Psychiatric Research, Vol. 74, p. 17.


    Wynaden, Dianne Tohotoa, Jenny Heslop, Karen and Al Omari, Omar 2016. Recognising falls risk in older adult mental health patients and acknowledging the difference from the general older adult population. Collegian, Vol. 23, Issue. 1, p. 97.


    Chang, Ki Jung Hong, Chang Hyung Lee, Yunhwan Lee, Kang Soo Roh, Hyun Woong Back, Joung Hwan Jung, Young Ki Lim, Ki Young Noh, Jai Sung Kim, Hyun Chung Choi, Seong Hye Kim, Seong Yoon Na, Duk L. Seo, Sang Won Lee, Soojin and Son, Sang Joon 2015. Effect of Psychotropic Drugs on Development of Diabetes Mellitus in Patients With Alzheimerʼs Disease. Medicine, Vol. 94, Issue. 23, p. e919.


    de Souto Barreto, Philipe Demougeot, Laurent Pillard, Fabien Lapeyre-Mestre, Maryse and Rolland, Yves 2015. Exercise training for managing behavioral and psychological symptoms in people with dementia: A systematic review and meta-analysis. Ageing Research Reviews, Vol. 24, p. 274.


    Hoffmann, Kristine Sobol, Nanna A. Frederiksen, Kristian S. Beyer, Nina Vogel, Asmus Vestergaard, Karsten Brændgaard, Hans Gottrup, Hanne Lolk, Annette Wermuth, Lene Jacobsen, Søren Laugesen, Lars P. Gergelyffy, Robert G. Høgh, Peter Bjerregaard, Eva Andersen, Birgitte B. Siersma, Volkert Johannsen, Peter Cotman, Carl W. Waldemar, Gunhild and Hasselbalch, Steen G. 2015. Moderate-to-High Intensity Physical Exercise in Patients with Alzheimer’s Disease: A Randomized Controlled Trial. Journal of Alzheimer's Disease, Vol. 50, Issue. 2, p. 443.


    Kuronen, Marja Koponen, Hannu Nykänen, Irma Karppi, Pertti and Hartikainen, Sirpa 2015. Use of anti-dementia drugs in home care and residential care and associations with neuropsychiatric symptoms: a cross-sectional study. BMC Geriatrics, Vol. 15, Issue. 1,


    Molano, Jennifer Rose V. Bratt, Robin and Shatz, Rhonna 2015. Treatment and Management of Dementia Due to Alzheimer’s Disease. Current Treatment Options in Neurology, Vol. 17, Issue. 8,


    Page, Amy Potter, Kathleen Clifford, Rhonda McLachlan, Andrew and Etherton-Beer, Christopher 2015. Prescribing for Australians living with dementia: study protocol using the Delphi technique. BMJ Open, Vol. 5, Issue. 8, p. e008048.


    Tan, Lin Tan, Lan Wang, Hui-Fu Wang, Jun Tan, Chen-Chen Tan, Meng-Shan Meng, Xiang-Fei Wang, Chong and Yu, Jin-Tai 2015. RETRACTED ARTICLE: Efficacy and safety of atypical antipsychotic drug treatment for dementia: a systematic review and meta-analysis. Alzheimer's Research & Therapy, Vol. 7, Issue. 1,


    Teipel, Stefan J. Thyrian, Jochen René Hertel, Johannes Eichler, Tilly Wucherer, Diana Michalowsky, Bernhard Kilimann, Ingo and Hoffmann, Wolfgang 2015. Neuropsychiatric symptoms in people screened positive for dementia in primary care. International Psychogeriatrics, Vol. 27, Issue. 01, p. 39.


    van der Spek, Klaas Gerritsen, Debby L. Smalbrugge, Martin Nelissen-Vrancken, Marjorie H.J.M.G. Wetzels, Roland B. Smeets, Claudia H.W. Zuidema, Sytse U. and Koopmans, Raymond T.C.M. 2015. A reliable and valid index was developed to measure appropriate psychotropic drug use in dementia. Journal of Clinical Epidemiology, Vol. 68, Issue. 8, p. 903.


    Yu, Fang 2015. The Encyclopedia of Adulthood and Aging.


    Brandt, Nicole J. and Turner, Traci 2014. Potentially inappropriate medications in older adults: A review of the 2012 Beers Criteria and the implications in persons with dementia. Mental Health Clinician, Vol. 4, Issue. 4, p. 166.


    Calvó-Perxas, Laia Turró-Garriga, Oriol Aguirregomozcorta, Maria Bisbe, Josep Hernández, Erélido López-Pousa, Secundino Manzano, Anna Palacios, Mónica Pericot-Nierga, Imma Perkal, Héctor Ramió, Lluís Vilalta-Franch, Joan and Garre-Olmo, Josep 2014. Psychotropic Drugs in Patients With Alzheimer's Disease: A Longitudinal Study by the Registry of Dementias of Girona (ReDeGi) in Catalonia, Spain. Journal of the American Medical Directors Association, Vol. 15, Issue. 7, p. 497.


    Desai, Abhilash K. and Galliano Desai, Faith 2014. Management of Behavioral and Psychological Symptoms of Dementia. Current Geriatrics Reports, Vol. 3, Issue. 4, p. 259.


    Langballe, Ellen Melbye Engdahl, Bo Nordeng, Hedvig Ballard, Clive Aarsland, Dag and Selbæk, Geir 2014. Short- and Long-term Mortality Risk Associated with the Use of Antipsychotics Among 26,940 Dementia Outpatients: A Population-Based Study. The American Journal of Geriatric Psychiatry, Vol. 22, Issue. 4, p. 321.


    ×

Pharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: a systematic review

  • Dallas P. Seitz (a1), Sudeep S. Gill (a2), Nathan Herrmann (a3) (a4), Sarah Brisbin (a1), Mark J. Rapoport (a3) (a4), Jenna Rines (a1), Kimberley Wilson (a5), Ken Le Clair (a1) and David K. Conn (a3) (a6)
  • DOI: http://dx.doi.org/10.1017/S1041610212001627
  • Published online: 19 October 2012
Abstract
ABSTRACT

Background: Medications are frequently prescribed for neuropsychiatric symptoms (NPS) associated with dementia, although information on the efficacy and safety of medications for NPS specifically in long-term care (LTC) settings is limited. The objective of this study was to provide a current review of the efficacy and safety of pharmacological treatments for NPS in LTC.

Methods: We searched MEDLINE, EMBASE, PsychINFO, and the Cochrane Library for randomized controlled trials comparing medications with either placebo or other interventions in LTC. Study quality was described using the Cochrane collaboration risk of bias tool. The efficacy of medications was evaluated using NPS symptom rating scales. Safety was evaluated through rates of trial withdrawals, trial withdrawals due to adverse events, and mortality.

Results: A total of 29 studies met inclusion criteria. The most common medications evaluated in studies were atypical antipsychotics (N = 15), typical antipsychotics (N = 7), anticonvulsants (N = 4), and cholinesterase inhibitors (N = 3). Statistically significant improvements in NPS were noted in some studies evaluating risperidone, olanzapine, and single studies of aripiprazole, carbamazepine, estrogen, cyproterone, propranolol, and prazosin. Study quality was difficult to rate in many cases due to incomplete reporting of details. Some studies reported higher rates of trial withdrawals, adverse events, and mortality associated with medications.

Conclusions: We conclude that there is limited evidence to support the use of some atypical antipsychotics and other medications for NPS in LTC populations. However, the generally modest efficacy and risks of adverse events highlight the need for the development of safe and effective pharmacological and non-pharmacological interventions for this population.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Pharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: a systematic review
      Your Kindle email address
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about sending content to Dropbox.

      Pharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: a systematic review
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about sending content to Google Drive.

      Pharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: a systematic review
      Available formats
      ×
Copyright
The online version of this article is published within an Open Access environment subject to the conditions of the Creative Commons Attribution-NonCommercial-ShareAlike licence <http://creativecommons.org/licenses/by-nc-sa/3.0/>. The written permission of Cambridge University Press must be obtained for commercial re-use.
Corresponding author
Correspondence should be addressed to: Dr. Dallas Seitz, Geriatric Psychiatry Services, Providence Care – Mental Health Services, 752 King Street West, Kingston, Ontario, Canada, K7L 4X3. Telephone: 613-548-5567, ext: 5942; Fax: 613-540-6128. Email: seitzd@providencecare.ca
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

C. Andrade , S. Sandarsh , K. B. Chethan and K. S. Nagesh (2010). Serontonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and reconsideration of mechanisms. Journal of Clinical Psychiatry, 71, 15651575.

C. Ballard and R. Howard (2006). Neuroleptic drugs in dementia: benefits and harm. Nature Reviews Neuroscience, 7, 492500.

C. G. Ballard et al. (2004). A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome. Journal of Clinical Psychiatry, 65, 114119.

C. Ballard et al. (2005). Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. British Medical Journal, 330, 874.

C. Ballard et al. (2008). A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (The DART-AD Trial). PLoS Medicine, 5, 05870599.

C. Ballard , A. Corbett , R. Chitramohan and D. Aarsland (2009a). Management of agitation and aggression associated with Alzheimer's disease: controversies and possible solutions. Current Opinion in Psychiatry, 22, 532540.

C. Ballard et al. (2009b). Management of agitation and aggression associated with Alzheimer disease. Nature Reviews Neurology, 5, 245255.

C. Ballard et al. (2009c). The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. The Lancet Neurology, 8, 151157.

N. Bharani and M. Snowden (2005). Evidence-based interventions for nursing home residents with dementia-related behavioral symptoms. Psychiatric Clinics of North America, 28, 9851005.

S. Borson and M. A. Raskind (1997). Clinical features and pharmacologic treatment of behavioral symptoms of Alzheimer's disease. Neurology, 48, S17.

H. Brodaty et al. (2003). A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. Journal of Clinical Psychiatry, 64, 134143.

B. J. Burns , H. R. Wagner , J. E. Taube , J. Magaziner , T. Permutt and L. R. Landerman (1993). Mental health service use by the elderly in nursing homes. American Journal of Public Health, 83, 331337.

M. Cantillon , R. Brunswick , D. Molina and M. Bahro (1996). Buspirone vs. haloperidol: a double-blind trial for agitation in a nursing home population with Alzheimer's disease. American Journal of Geriatric Psychiatry, 4, 263267.

J. Cohen-Mansfield and B. Jensen (2008). Nursing home physicians’ knowledge of and attitudes toward nonpharmacological interventions for treatment of behavioral disturbances associated with dementia. Journal of the American Medical Directors Association, 9, 491498.

J. Cohen-Mansfield and A. Libin (2004). Assessment of agitation in elderly patients with dementia: correlations between informant rating and direct observation. International Journal of Geriatric Psychiatry, 19, 881889.

J. Cohen-Mansfield and J. E. Mintzer (2005). Time for change: the role of nonpharmacological interventions in treating behavior problems in nursing home residents with dementia. Alzheimer Disease and Associated Disorders, 19, 3740.

J. Cohen-Mansfield , S. Lipson , P. Werner , N. Billig , L. Taylor and R. Woosley (1999). Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home. Archives of Internal Medicine, 159, 17331740.

J. Cohen-Mansfield , K. Thein , M. S. Marx and D. Dakheel-Ali (2012). What are the barriers to performing nonpharmacological interventions for behavioral symptoms in the nursing home? Journal of the American Medical Directors Association, 13, 400405.

D. K. Conn and D. P. Seitz (2010). Advances in the treatment of psychiatric disorders in long-term care homes. Current Opinion in Psychiatry, 23, 516521.

C. Cooney , A. Mortimer , A. Smith , K. Newton and M. Wrigley (1996). Carbamazepine use in aggressive behaviour associated with senile dementia. International Journal of Geriatric Psychiatry, 11, 901905.

P. P. De Deyn et al. (1999 ). A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology, 53, 946955.

P. P. De Deyn et al. (2004). Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry, 19, 115126.

T. J. Fabian et al. (2004). Paroxetine-induced hyponatremia in older adults. Archives of Internal Medicine, 164, 327332.

T. Fahey , A. A. Montgomery , J. Barnes and J. Protheroe (2003). Quality of care for elderly residents in nursing homes and elderly people living at home: controlled observational study. BMJ, 326, 580584.

C. S. Fontaine , L. S. Hynan , K. Koch , K. Martin-Cook , D. Svetlik and M. F. Weiner (2003). A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities. Journal of Clinical Psychiatry, 64, 726730.

S. Gaber , S. Ronzoli , A. Bruno and A. Biagi (2001). Sertraline versus small doses of haloperidol in the treatment of agitated behavior in patients with dementia. Archives of Gerontology and Geriatrics, 33 (Suppl.), 159162.

P. R. Gehrman , D. J. Connor , J. L. Martin , T. Shochat , J. Corey-Bloom and S. Ancoli-Israel (2009). Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with Alzheimer disease. American Journal of Geriatric Psychiatry, 17, 166169.

S. S. Gill et al. (2005). Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. British Medical Journal, 330, 445.

S. S. Gill et al. (2007). Antipsychotic drug use and mortality in older adults with dementia. Annals of Internal Medicine, 146, 775786.

A. L. Gruber-Baldini , M. Boustani , P. D. Sloane and S. Zimmerman (2004). Behavioral symptoms in residential care/assisted living facilities: prevalence, risk factors, and medication management. Journal of the American Geriatrics Society, 52, 16101617.

N. Herrmann and K. L. Lanctot (2005). Do atypical antipsychotics cause stroke? CNS Drugs, 19, 91103.

N. Herrmann , M. Mamdani and K. L. Lanctot (2004). Atypical antipsychotics and risk of cerebrovascular accidents. American Journal of Psychiatry, 161, 1113.

N. Herrmann , S. Gauthier and P. G. Lysy (2007). Clinical practice guidelines for severe Alzheimer's disease. Alzheimer's and Dementia, 3, 385397.

T. T. Hien Le et al. (2005). Aytypical antipsychotic medications and risk of falls in residents of aged care facilities. Journal of the American Geriatrics Society, 53, 12901295.

J. P. T. Higgins and S. Green (2008). Cochrane Handbook for Systematic Reviews of Interventions. Chichester, UK: Wiley.

C. Holmes et al. (2007). Risperidone and rivastigmine and agitated behaviour in severe Alzheimer's disease: a randomised double blind placebo controlled study. International Journal of Geriatric Psychiatry, 22, 380381.

R. J. Howard et al. (2007). Donepezil for the treatment of agitation in Alzheimer's disease. New England Journal of Medicine, 357, 13821392.

D. Huertas et al. (2007). Antiaggressive effect of cyproterone versus haloperidol in Alzheimer's disease: a randomized double-blind pilot study. Journal of Clinical Psychiatry, 68, 439444.

J. J. Jalbert , C. B. Eaton , S. C. Miller and K. L. Lapane (2010). Antipsychotic use and the risk of hip fracture among older adults afflicted with dementia. Journal of the American Medical Directors Association, 11, 120127.

H. C. Kales et al. (2007). Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. American Journal of Psychiatry, 164, 15681576.

H. C. Kales et al. (2011). Trends in antipsychotic use in dementia 1999–2007. Archives of General Psychiatry, 68, 190197.

I. R. Katz , D. V. Jeste , J. E. Mintzer , C. Clyde , J. Napolitano and M. Brecher (1999). Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. Journal of Clinical Psychiatry, 60, 107115.

S. S. Kindermann , C. R. Dolder , A. Bailey , I. R. Katz and D. V. Jeste (2002). Pharmacological treatment of psychosis and agitation in elderly patients with dementia: four decades of experience. Drugs and Aging, 19, 257276.

M. N. Kozman , J. Wattis and S. Curran (2006). Pharmacological management of behavioral and psychological disturbance in dementia. Human Psychopharmacology: Clinical and Experimental, 21, 112.

H. H. Kyomen , A. Satlin , J. Hennen and J. Y. Wei (1999). Estrogen therapy and aggressive behavior in elderly patients with moderate-to-severe dementia. Results from a short-term, randomized, double-blind trial. American Journal of Geriatric Psychiatry, 7, 339348.

K. L. Lanctot et al. (1998). Efficacy and safety of neuroleptics in behavioral disorders associated with dementia. Journal of Clinical Psychiatry, 59, 550561; quiz 562–563.

A. Larrayadieu et al. (2011). Associated factors with antipsychotic use in assisted living facilities: a cross-sectional study in 4367 residents. Age and Ageing, 40, 368375.

J. Lexchin , L. A. Bero , B. Djulbegovic and O. Clark (2003). Pharmaceutical industry sponsorship and research outcome and quality: systematic review. British Medical Journal, 326, 11671170.

S. Meeks (1996). Psychological consultation to nursing homes: description of a six-year practice. Psychotherapy, 33, 1929.

J. Mintzer et al. (2006). Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial. American Journal of Geriatric Psychiatry, 14, 280291.

J. E. Mintzer et al. (2007). Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. American Journal of Geriatric Psychiatry, 15, 918931.

D. Moher , A. Liberati , J. Tetzlaff , D. G. Altman and The Prisma Group. (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Medicine, 6, e1000097.

J. T. Olin , L. S. Fox , S. Pawluczyk , N. A. Taggart and L. S. Schneider (2001). A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease. American Journal of Geriatric Psychiatry, 9, 400405.

E. R. Peskind et al. (2005). Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer disease: a placebo-controlled study. Alzheimer Disease and Associated Disorders, 19, 2328.

K. H. Pitkala , J. Laurila , T. Strandberg and R. Tilvis (2004). Behavioral symptoms and the administration of psychotropic drugs to aged patients with dementia in nursing homes and in acute geriatric wards. International Psychogeriatrics, 16, 6174.

B. G. Pollock et al. (2002). Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. The American Journal of Psychiatry, 159, 460465.

B. G. Pollock et al. (2007). A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. American Journal of Geriatric Psychiatry, 15, 942952.

A. P. Porsteinsson et al. (2001). Placebo-controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry, 9, 5866.

S. A. Rappaport , R. N. Marcus , G. Manos , R. D. McQuade and D. A. Oren (2009). A randomized, double-blind, placebo-controlled tolerability study of intramuscular aripiprazole in acutely agitated patients with Alzheimer's, vascular, or mixed dementia. Journal of the American Medical Directors Association, 10, 2127.

W. E. Reichman et al. (1998). Psychiatric consultation in the nursing home: a survey of six states. American Journal of Geriatric Psychiatry, 6, 320327.

P. A. Rochon et al. (2007). Variation in nursing home antipsychotic prescribing rates. Archives of Internal Medicine, 167, 676683.

P. A. Rochon et al. (2008). Antipsychotic therapy and short-term serious events in older adults with dementia. Archives of Internal Medicine, 168, 10901096.

S. Ruths , J. Straand , H. A. Nygaard , B. Bjorvatn and S. Pallesen (2004). Effect of antipsychotic withdrawal on behavior and sleep/wake activity in nursing home residents with dementia: a randomized, placebo-controlled, double-blinded study the bergen district nursing home study. Journal of the American Geriatrics Society, 52, 17371743.

S. Ruths , J. Straand , H. A. Nygaard and D. Aarsland (2008). Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo-controlled study – the Bergen District Nursing Home Study (BEDNURS). International Journal of Geriatric Psychiatry, 23, 889895.

S. Saddichha and V. Pandey (2008). Alzheimer's and non-Alzheimer's dementia: a critical review of pharmacological and nonpharmacological strategies. American Journal of Alzheimer's Disease and Other Dementias, 23, 150161.

L. S. Schneider , K. S. Dagerman and P. Insel (2005). Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. Journal of the American Medical Association, 294, 19341943.

L. S. Schneider , V. E. Pollock and S. A. Lyness (1990). A metaanalysis of controlled trials of neuroleptic treatment in dementia. Journal of the American Geriatrics Society, 38, 553563.

L. S. Schneider , K. Dagerman and P. S. Insel (2006a). Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. American Journal of Geriatric Psychiatry, 14, 191210.

L. S. Schneider et al. (2006b). Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. New England Journal of Medicine, 355, 15251538.

D. P. Seitz et al. (2012). Efficacy and feasibility of non-pharmacological interventions for neuropsychiatric symptoms of dementia in long-term care: a systematic review. Journal of the American Medical Directors Association, 13, 503506.e2.

G. Selbaek , O. Kirkevold and K. Engedal (2007). The prevalence of psychiatric symptoms and behavioural disturbances and the use of psychotropic drugs in Norwegian nursing homes. International Journal of Geriatric Psychiatry, 22, 843849.

G. Selbaek , O. Kirkevold and K. Engedal (2008). The course of psychiatric and behavioral symptoms and the use of psychotropic medication in patients with dementia in Norwegian nursing homes – a 12-month follow-up study. American Journal of Geriatric Psychiatry, 16, 528536.

K. M. Sink , K. F. Holden and K. Yaffe (2005). Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. Journal of the American Medical Association, 293, 596608.

M. Snowden , K. Sato and P. Roy-Byrne (2003 ). Assessment and treatment of nursing home residents with depression or behavioral symptoms associated with dementia: a review of the literature. Journal of the American Geriatrics Society, 51, 13051317.

O. H. Sommer , O. Aga , M. Cvancarova , I. C. Olsen , G. Selbaek and K. Engedal (2009). Effect of oxcarbazepine in the treatment of agitation and aggression in severe dementia. Dementia and Geriatric Cognitive Disorders, 27, 155163.

J. S. Street et al. (2000). Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. Archives of General Psychiatry, 57, 968976.

J. E. Streim et al. (2008). A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease. American Journal of Geriatric Psychiatry, 16, 537550.

D. L. Sultzer et al. (2008). Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. American Journal of Psychiatry, 165, 844854.

B. Sutor , T. A. Rummans and G. E. Smith (2001). Assessment and management of behavioral disturbances in nursing home patients with dementia. Mayo Clinic Proceedings, 76, 540550.

B. Takkouche , A. Montes-Martinez , S. S. Gill and M. Etminan (2007). Psychotropic medications and the risk of fracture: a meta-analysis. Drug Safety, 30, 171184.

P. N. Tariot et al. (1998 ). Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. American Journal of Psychiatry, 155, 5461.

P. N. Tariot et al. (2001). A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society, 49, 15901599.

P. N. Tariot et al. (2005). Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. American Journal of Geriatric Psychiatry, 13, 942949.

P. N. Tariot et al. (2006). Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. American Journal of Geriatric Psychiatry, 14, 767776 [Erratum: (2006). American Journal of Geriatric Psychiatry, 14, 988].

P. N. Tariot et al. (2011). Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Archives of General Psychiatry, 68, 853861.

G. Trifiro , J. Dieleman , E. F. Sen , G. Gambassi and M. C. Sturkenboom (2010). Risk of ischemic stroke associated with antidepressant drug use in elderly persons. Journal of Clinical Psychopharmacology, 30, 252258.

E. H. Turner , A. M. Matthews , E. Linardatos , R. A. Tell and R. Rosenthal (2008). Selective publication of antidepressant trials and its influence on apparent efficacy. New England Journal of Medicine, 358, 252260.

F. R. J. Verhey , M. Verkaaik and R. Lousberg (2006). Olanzapine versus haloperidol in the treatment of agitation in elderly patients with dementia: results of a randomized controlled double-blind trial. Dementia and Geriatric Cognitive Disorders, 21, 18.

P. Vestergaard , L. Rejnmark and L. Mosekilde (2006). Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporosis International, 17, 807816.

C. L. Vigen et al. (2011). Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. American Journal of Psychiatry, 168, 831839.

P. S. Wang et al. (2005). Risk of death in elderly users of conventional vs. atypical antipsychotic medications. New England Journal of Medicine, 353, 23352341.

L. Y. Wang et al. (2009). Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. American Journal of Geriatric Psychiatry, 17, 744751.

C. S. Wu , S. C. Wang , Y. C. Cheng and S. S. Gau (2011). Association of cerebrovascular events with antidepressant use: a case-crossover study. American Journal of Psychiatry, 168, 511521.

K. X. Zhong , P. N. Tariot , J. Mintzer , M. C. Minkwitz and N. A. Devine (2007). Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study. Current Alzheimer Research, 4, 8193.

S. Zuidema , R. Koopmans and F. Verhey (2007). Prevalence and predictors of neuropsychiatric symptoms in cognitively impaired nursing home patients. Journal of Geriatric Psychiatry and Neurology, 20, 4149.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

International Psychogeriatrics
  • ISSN: 1041-6102
  • EISSN: 1741-203X
  • URL: /core/journals/international-psychogeriatrics
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords: